Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBR854 cell injection plus pazopanib versus pazopanib alone in advanced renal cell carcinoma
CTR20252963Phase 2Active
- Sponsor
- InnoBairui
- Start
- Sep 2025
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing IBR854 Cell Injection + pazopanib with pazopanib monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Sep 2025; status: active.
02
Drugs
IBR854pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20252963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252963.